{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:11:19Z","timestamp":1781554279291,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T00:00:00Z","timestamp":1462320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00280-016-3046-2","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T15:57:47Z","timestamp":1462377467000},"page":"1263-1273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2"],"prefix":"10.1007","volume":"77","author":[{"given":"Aziz","family":"Ouerdani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Goutagny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Kalamarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki F.","family":"Troc\u00f3niz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ribba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,4]]},"reference":[{"key":"3046_CR1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jmg.29.12.847","volume":"29","author":"DGR Evans","year":"1992","unstructured":"Evans DGR, Huson SM, Donnai D et al (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 29:847\u2013852. doi: 10.1136\/jmg.29.12.847","journal-title":"J Med Genet"},{"key":"3046_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","volume":"158 A","author":"JO Blakeley","year":"2012","unstructured":"Blakeley JO, Evans DG, Adler J et al (2012) Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet Part A 158 A:24\u201341. doi: 10.1002\/ajmg.a.34359","journal-title":"Am J Med Genet Part A"},{"key":"3046_CR3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","volume":"13","author":"GG Chiang","year":"2007","unstructured":"Chiang GG, Abraham RT (2007) Targeting the mTOR signaling network in cancer. Trends Mol Med 13:433\u2013442. doi: 10.1016\/j.molmed.2007.08.001","journal-title":"Trends Mol Med"},{"key":"3046_CR4","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","volume":"13","author":"H P\u00f3pulo","year":"2012","unstructured":"P\u00f3pulo H, Lopes JM, Soares P (2012) The mTOR signalling pathway in human cancer. Int J Mol Sci 13:1886\u20131918. doi: 10.3390\/ijms13021886","journal-title":"Int J Mol Sci"},{"key":"3046_CR5","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","volume":"10","author":"BI Rini","year":"2009","unstructured":"Rini BI, Atkins MB (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10:992\u20131000. doi: 10.1016\/S1470-2045(09)70240-2","journal-title":"Lancet Oncol"},{"key":"3046_CR6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358\u2013367. doi: 10.1056\/NEJMoa0902579","journal-title":"N Engl J Med"},{"key":"3046_CR7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","volume":"12","author":"V Mautner","year":"2010","unstructured":"Mautner V, Nguyen R, Kutta H et al (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14\u201318. doi: 10.1093\/neuonc\/nop010","journal-title":"Neuro Oncol"},{"key":"3046_CR8","author":"MC Alanin","year":"2014","unstructured":"Alanin MC, Klausen C, Caye-Thomasen P et al (2014) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Oto-Rhino-Laryngol. doi: 10.1007\/s00405-014-3398-3","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"3046_CR9","author":"S Farschtschi","year":"2015","unstructured":"Farschtschi S, Kollmann P, Dalchow C et al (2015) Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2. Eur Arch Oto-Rhino-Laryngol. doi: 10.1007\/s00405-015-3604-y","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"3046_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M et al (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 122:313\u2013320. doi: 10.1007\/s11060-014-1710-0","journal-title":"J Neurooncol"},{"key":"3046_CR11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Hagiwara M et al (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 16:292\u2013297. doi: 10.1093\/neuonc\/not150","journal-title":"Neuro Oncol"},{"key":"3046_CR12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0035-3787(07)91459-9","volume":"163","author":"S Goutagny","year":"2007","unstructured":"Goutagny S, Bouccara D, Bozorg-Grayeli A et al (2007) La neurofibromatose de type 2. Rev Neurol (Paris) 163:765\u2013777. doi: 10.1016\/S0035-3787(07)91459-9","journal-title":"Rev Neurol (Paris)"},{"key":"3046_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","volume":"93","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Halpin C, Blakeley JO et al (2009) Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 93:61\u201367. doi: 10.1007\/s11060-009-9867-7","journal-title":"J Neurooncol"},{"key":"3046_CR14","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1158\/0008-5472.CAN-14-2584","volume":"75","author":"N Buil-Bruna","year":"2015","unstructured":"Buil-Bruna N, Sahota T, Lopez-Picazo J-M et al (2015) Early prediction of disease progression in small cell lung cancer: toward model-based personalized medicine in oncology. Cancer Res 75:2416\u20132425. doi: 10.1158\/0008-5472.CAN-14-2584","journal-title":"Cancer Res"},{"key":"3046_CR15","author":"P Mazzocco","year":"2015","unstructured":"Mazzocco P, Barth\u00e9l\u00e9my C, Kaloshi G et al (2015) Prediction of response to temozolomide in low-grade glioma patients based on tumor size dynamics and genetic characteristics. CPT Pharmacomet Syst Pharmacol. doi: 10.1002\/psp4.54","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"3046_CR16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2307\/2532087","volume":"46","author":"MJ Lindstrom","year":"1990","unstructured":"Lindstrom MJ, Bates DM, Lindstrom MJ (1990) Nonlinear mixed effects models for repeated measures data. Biometrics 46:673\u2013687","journal-title":"Biometrics"},{"key":"3046_CR17","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development\u2014part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol 2:e38. doi: 10.1038\/psp.2013.14","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"3046_CR18","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1038\/psp.2014.12","volume":"3","author":"B Ribba","year":"2014","unstructured":"Ribba B, Holford NH, Magni P et al (2014) A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacomet Syst Pharmacol 3:e113. doi: 10.1038\/psp.2014.12","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"3046_CR19","unstructured":"Bauer RJ (2011) NONMEM users guide: introduction to NONMEM 7.2.0. ICON Development Solutions Ellicott City, Maryland"},{"key":"3046_CR20","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/0008-5472.CAN-03-2524","volume":"64","author":"M Simeoni","year":"2004","unstructured":"Simeoni M, Magni P, Cammia C et al (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094\u20131101","journal-title":"Cancer Res"},{"key":"3046_CR21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/74664","volume":"6","author":"P Schratzberger","year":"2000","unstructured":"Schratzberger P, Schratzberger G, Silver M et al (2000) Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 6:405\u2013413. doi: 10.1038\/74664","journal-title":"Nat Med"},{"key":"3046_CR22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/bies.20092","volume":"26","author":"E Storkebaum","year":"2004","unstructured":"Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays 26:943\u2013954. doi: 10.1002\/bies.20092","journal-title":"BioEssays"},{"key":"3046_CR23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1152\/physrev.00031.2008","volume":"89","author":"C Ruiz de Almodovar","year":"2009","unstructured":"Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P (2009) Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89:607\u2013648. doi: 10.1152\/physrev.00031.2008","journal-title":"Physiol Rev"},{"key":"3046_CR24","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1097\/00005537-200312000-00014","volume":"113","author":"P Caye-Thomasen","year":"2003","unstructured":"Caye-Thomasen P, Baandrup L, Jacobsen GK et al (2003) Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 113:2129\u20132134. doi: 10.1097\/00005537-200312000-00014","journal-title":"Laryngoscope"},{"key":"3046_CR25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/88842","volume":"28","author":"B Oosthuyse","year":"2001","unstructured":"Oosthuyse B, Moons L, Storkebaum E et al (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28:131\u2013138","journal-title":"Nat Genet"},{"key":"3046_CR26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","volume":"62","author":"J-F Lu","year":"2008","unstructured":"Lu J-F, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779\u2013786. doi: 10.1007\/s00280-007-0664-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"3046_CR27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-015-2701-3","volume":"75","author":"E Panoilia","year":"2015","unstructured":"Panoilia E, Schindler E, Samantas E et al (2015) A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol 75:791\u2013803. doi: 10.1007\/s00280-015-2701-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"3046_CR28","unstructured":"Roche (2014) Avastin data sheet"},{"key":"3046_CR29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","volume":"1","author":"LM Ballou","year":"2008","unstructured":"Ballou LM, Lin RZ (2008) Rapamycin and mTOR kinase inhibitors. J Chem Biol 1:27\u201336. doi: 10.1007\/s12154-008-0003-5","journal-title":"J Chem Biol"},{"key":"3046_CR30","unstructured":"FDA (2008) Everolimus clinical pharmacology and biopharmaceutics review(s)"},{"key":"3046_CR31","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","volume":"15","author":"HA Lane","year":"2009","unstructured":"Lane HA, Wood JM, McSheehy PMJ et al (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15:1612\u20131622. doi: 10.1158\/1078-0432.CCR-08-2057","journal-title":"Clin Cancer Res"},{"key":"3046_CR32","author":"A Ouerdani","year":"2015","unstructured":"Ouerdani A, Struemper H, Suttle AB et al (2015) Preclinical modeling of tumor growth and angiogenesis inhibition to describe pazopanib clinical effects in renal cell carcinoma. CPT Pharmacomet Syst Pharmacol. doi: 10.1002\/psp4.12001","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"3046_CR33","first-page":"34","volume":"28","author":"M Barbara","year":"2008","unstructured":"Barbara M, Ronchetti F, Manni V, Monini S (2008) Double localization of a unilateral sporadic vestibular schwannoma. Acta Otorhinolaryngol Ital 28:34\u201337","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"3046_CR34","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/MAO.0b013e318263d315","volume":"33","author":"G Tryggvason","year":"2012","unstructured":"Tryggvason G, Barnett A, Kim J et al (2012) Radiographic association of schwannomas with sensory ganglia. Otol Neurotol 33:1276\u20131282. doi: 10.1097\/MAO.0b013e318263d315.Radiographic","journal-title":"Otol Neurotol"},{"key":"3046_CR35","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1159\/000370191","volume":"20","author":"A Bozorg Grayeli","year":"2015","unstructured":"Bozorg Grayeli A, Ferrary E, Fl Tubach et al (2015) Effect of corticosteroids on facial function after cerebellopontine angle tumor removal: a double-blind study versus placebo. Audiol Neurotol 20:2013\u20132221. doi: 10.1159\/000370191","journal-title":"Audiol Neurotol"},{"key":"3046_CR36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/neuonc\/nor101","volume":"13","author":"M Peyre","year":"2011","unstructured":"Peyre M, Goutagny S, Imbeaud S et al (2011) Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. Neuro Oncol 13:1125\u20131132. doi: 10.1093\/neuonc\/nor101","journal-title":"Neuro Oncol"},{"key":"3046_CR37","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She Q-B (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500\u20131508. doi: 10.1158\/0008-5472.CAN-05-2925","journal-title":"Cancer Res"},{"key":"3046_CR38","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455\u20137464. doi: 10.1038\/sj.onc.1209085","journal-title":"Oncogene"},{"key":"3046_CR39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40136-014-0063-8","volume":"2","author":"C Miller","year":"2014","unstructured":"Miller C, Sudhoff H, Jacob A (2014) Vestibular schwannoma drug development: current state-of-the art. Curr Otorhinolaryngol Rep 2:217\u2013225. doi: 10.1007\/s40136-014-0063-8","journal-title":"Curr Otorhinolaryngol Rep"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3046-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3046-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3046-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:07:41Z","timestamp":1559038061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3046-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,4]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3046"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3046-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,4]]}}}